Welcome to our dedicated page for Monopar Therapeutics news (Ticker: MNPR), a resource for investors and traders seeking the latest updates and insights on Monopar Therapeutics stock.
Monopar Therapeutics Inc. (Nasdaq: MNPR) is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics aimed at prolonging life and enhancing the quality of life for cancer patients. Founded in 2014 and headquartered in Wilmette, Illinois, the company has made significant strides in the oncology sector with a robust pipeline of innovative treatments.
Monopar's leading candidate, Validive®, is a clonidine mucobuccal tablet currently in Phase III clinical trials. It aims to treat severe oral mucositis in patients undergoing radiation therapy for oropharyngeal cancer. Another key product, camsirubicin, is a next-generation analog of doxorubicin designed to limit cardiotoxicity while retaining its anticancer efficacy. This compound is presently in a Phase 1b dose-escalation trial for soft tissue sarcoma.
Additionally, Monopar is developing MNPR-101, a humanized monoclonal antibody targeting the urokinase plasminogen activator receptor (uPAR) for the treatment of advanced solid tumors and severe COVID-19. The company's MNPR-101-Zr is currently enrolling patients in a Phase 1 dosimetry clinical trial to evaluate its safety and biodistribution in various advanced cancers.
Monopar has established strategic partnerships to bolster its research and development efforts. The collaboration with Grupo Español de Investigación en Sarcomas is pivotal for advancing camsirubicin, while the partnership with NorthStar Medical Radioisotopes focuses on developing radio-immuno-therapeutics, including the supply of actinium-225 (Ac-225) for MNPR-101.
Financially, Monopar reported significant progress in reducing net loss from $10.5 million in 2022 to $8.4 million in 2023. The company ended 2023 with $7.3 million in cash and additional funding of $3.2 million expected in Q1 2024. These resources are projected to sustain operations through June 2025, enabling Monopar to reach key clinical milestones.
For more information on Monopar Therapeutics and their groundbreaking work in oncology, visit www.monopartx.com.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced that Dr. Chandler Robinson, the CEO, will present at the Jefferies Radiopharma Innovation Summit on April 3, 2023, from 1:00 to 1:30 pm at the Jefferies Conference Center in NYC.
The company focuses on developing therapeutics aimed at extending life and improving the quality of life for cancer patients. Their pipeline includes camsirubicin (Phase 1b) for advanced soft tissue sarcoma and MNPR-101 for radiopharmaceutical use in advanced cancers. Monopar is committed to enhancing cancer patient care through innovation.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced the completion of a pre-specified interim analysis for its Phase 2b/3 VOICE trial, which aimed to prevent severe oral mucositis in patients with oropharyngeal cancer undergoing chemoradiotherapy. The independent Data Safety Monitoring Board reported that the trial did not meet the pre-defined efficacy threshold of a 15% absolute difference in SOM prevention between Validive and placebo, leading to the discontinuation of the study and Validive's development. Monopar plans to redirect resources towards advancing its Phase 1b camsirubicin trial and MNPR-101 radiopharmaceutical program, stating it has sufficient funds to support activities beyond Q1 2024.
Monopar Therapeutics (Nasdaq: MNPR) announced its financial results for Q4 and full year 2022. As of December 31, 2022, cash and investments totaled $13.1 million, expected to fund ongoing trials. The VOICE trial anticipates an interim analysis by next week to determine continuation. The camsirubicin Phase 1b trial has begun enrolling at a higher dose level, showing promising data in progression-free survival and lower toxicity than doxorubicin. Recent preclinical studies on MNPR-101 and MNPR-202 indicate potential advancements. However, a net loss of $10.5 million was reported for 2022.
Monopar Therapeutics (Nasdaq: MNPR), a biopharmaceutical company dedicated to cancer therapeutics, announced that CEO Chandler Robinson will participate in a fireside chat at the 35th Annual Roth Conference.
Event Details:
Date: March 13, 2023
Time: 12:30-1:00 pm PT
Location: The Ritz Carlton, Laguna Niguel, Dana Point, California.
Monopar's pipeline includes Validive® (Phase 2b/3) for severe oral mucositis, camsirubicin (Phase 1b) for soft tissue sarcoma, and MNPR-101 & MNPR-202 for advanced cancers. For more information, visit www.monopartx.com.
Monopar Therapeutics (Nasdaq: MNPR) and NorthStar Medical Radioisotopes have expanded their collaboration in the radiopharmaceutical sector, introducing a new imaging candidate, MNPR-101-Zr. Preclinical results indicate high uptake of MNPR-101-Zr in various tumors, supporting plans for a first-in-human imaging study by year-end. MNPR-101-Zr is a zirconium-89 labeled form of MNPR-101, targeted at the urokinase plasminogen activator receptor (uPAR). The partnership aims to leverage MNPR-101 for both imaging and therapeutic applications, highlighting the potential of personalized medicine in cancer treatment.
Monopar Therapeutics Inc. (Nasdaq: MNPR) has announced an update on its Phase 1b trial of camsirubicin for advanced soft tissue sarcoma (ASTS). Enrollment has begun for the fifth dose cohort at 650 mg/m2, nearly 2.5 times the highest dose previously evaluated. Notably, there has been no drug-related cardiotoxicity observed, in contrast to doxorubicin, the current standard treatment. Additionally, lower rates of hair loss and oral mucositis have been reported in patients treated with camsirubicin compared to those on doxorubicin. A second clinical trial site has also been established at the Fred Hutchinson Cancer Center in Seattle.
Monopar Therapeutics Inc. (Nasdaq: MNPR) announced plans to report key clinical updates over the next two months, focusing on:
- Interim analysis for the Validive Phase 2b/3 VOICE trial
- Clinical data from the camsirubicin Phase 1b trial
- Preclinical progress on the MNPR-101 RIT program
Notably, the camsirubicin Phase 1b trial has shown improved safety compared to doxorubicin, while enrollment for Validive's trial continues ahead of its expected analysis in March 2023. These updates are crucial for assessing the company's therapeutic pipeline aimed at improving cancer patient outcomes.
FAQ
What is the current stock price of Monopar Therapeutics (MNPR)?
What is the market cap of Monopar Therapeutics (MNPR)?
What is Monopar Therapeutics Inc.?
What are the key products in Monopar's pipeline?
What is the status of Validive®?
Who are Monopar's key partners?
What financial position does Monopar hold?
What is MNPR-101?
How has Monopar reduced its net loss?
What are the future plans for MNPR-101?
What collaborations support Monopar's MNPR-101 development?
Where can I find more information about Monopar?
